Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

   Completed · Phase 1, Phase 2 · Solid Neoplasms

   NCT04420884 · Takeda Pharmaceuticals U.S.A., Inc. · 24 U.S. investigators

   $3.5Mresearch payments

2. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

   Recruiting · Phase 1 · Alzheimer Disease

   NCT06297590 · Eli Lilly and Company · 7 U.S. investigators

   $3.5Mresearch payments

3. Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

   Active, not recruiting · Phase 3 · Leukemia

   NCT06578247 · Daiichi Sankyo Inc. · 34 U.S. investigators

   $3.4Mresearch payments

4. A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

   Active, not recruiting · Phase 3 · Diffuse Large B-Cell Lymphoma

   NCT05578976 · AbbVie Inc. · 58 U.S. investigators

   $3.4Mresearch payments

5. A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

   Completed · Phase 1 · Healthy Volunteer

   NCT06937619 · AbbVie Inc. · 3 U.S. investigators

   $3.4Mresearch payments

6. A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

   Active, not recruiting · Phase 1 · Metastatic Castration-Resistant Prostate Cancer

   NCT06318273 · AbbVie Inc. · 9 U.S. investigators

   $3.4Mresearch payments

7. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

   Recruiting · Phase 1, Phase 2 · Leukemia, Myeloid, Acute

   NCT04988555 · Sumitomo Pharma America, Inc. · 38 U.S. investigators

   $3.4Mresearch payments

8. Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

   Active, not recruiting · Phase 2 · Asthma

   NCT06676319 · Sanofi US Services Inc. · 57 U.S. investigators

   $3.4Mresearch payments

9. A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

   Completed · Phase 2 · Schizophrenia

   NCT05227703 · AbbVie Inc. · 16 U.S. investigators

   $3.4Mresearch payments

10. Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Active, not recruiting · Phase 1 · Recurrent Diffuse Large B-Cell Lymphoma

    NCT01955499 · AbbVie Inc. · 1 U.S. investigator

    $3.4Mresearch payments

11. Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

    Completed · Phase 3 · Mesopic Vision

    NCT06349759 · Oyster Point Pharma, Inc. · 38 U.S. investigators

    $3.4Mresearch payments

12. A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

    Completed · Phase 1 · Glabellar Lines

    NCT06834789 · AbbVie Inc. · 8 U.S. investigators

    $3.4Mresearch payments

13. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

    Active, not recruiting · Phase 3 · Hidradenitis Suppurativa

    NCT05889182 · AbbVie Inc. · 84 U.S. investigators

    $3.3Mresearch payments

14. A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

    Active, not recruiting · Phase 3 · Chronic Migraine

    NCT06047444 · Ipsen Innovation · 69 U.S. investigators

    $3.3Mresearch payments

15. Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

    Active, not recruiting · Phase 4 · Asthma

    NCT05097287 · Genzyme Corporation · 64 U.S. investigators

    $3.3Mresearch payments

16. A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

    Recruiting · Phase 1, Phase 2 · B-cell Malignancy

    NCT06634589 · Beone Medicines Ltd. · 15 U.S. investigators

    $3.3Mresearch payments

17. A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

    Completed · Phase 3 · Type 2 Diabetes

    NCT06045221 · Eli Lilly and Company · 80 U.S. investigators

    $3.3Mresearch payments

18. A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

    Active, not recruiting · Phase 3 · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

    NCT05063162 · UCB SA · 17 U.S. investigators

    $3.3Mresearch payments

19. Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

    Completed · Phase 1, Phase 2 · Norovirus Acute Gastroenteritis

    NCT05992935 · ModernaTX, Inc. · 14 U.S. investigators

    $3.3Mresearch payments

20. Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

    Completed · Phase 3 · Diabetes Type 2

    NCT06354660 · Eli Lilly and Company · 37 U.S. investigators

    $3.3Mresearch payments

21. Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

    Recruiting · Phase 3 · Progressive Pulmonary Fibrosis

    NCT05943535 · United Therapeutics Corporation · 67 U.S. investigators

    $3.2Mresearch payments

22. Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

    Recruiting · Phase 2 · Myelodysplastic Syndrome

    NCT06577441 · E.r. Squibb & Sons, L.l.c. · 37 U.S. investigators

    $3.2Mresearch payments

23. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

    Active, not recruiting · Phase 3 · Crohn's Disease

    NCT06063967 · AbbVie Inc. · 73 U.S. investigators

    $3.2Mresearch payments

24. A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

    Active, not recruiting · Phase 3 · Perennial Allergic Rhinitis (PAR)

    NCT06339008 · Eli Lilly and Company · 27 U.S. investigators

    $3.2Mresearch payments

25. LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

    Active, not recruiting · Phase 4 · Change in Bone Mineral Density

    NCT05303636 · Exeltis, USA Inc. · 28 U.S. investigators

    $3.2Mresearch payments

26. A Study of LY4268989 (MORF-057) in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06964776 · Eli Lilly and Company · 1 U.S. investigator

    $3.2Mresearch payments

27. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

    Recruiting · Phase 2 · Crohn's Disease

    NCT06548542 · AbbVie Inc. · 55 U.S. investigators

    $3.1Mresearch payments

28. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

    Active, not recruiting · Phase 3 · Metastatic Non Small Cell Lung Cancer

    NCT05555732 · Daiichi Sankyo Inc. · 29 U.S. investigators

    $3.1Mresearch payments

29. A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

    Completed · Phase 2 · Influenza

    NCT06508320 · ModernaTX, Inc. · 12 U.S. investigators

    $3.1Mresearch payments

30. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

    Active, not recruiting · Phase 2 · Chronic Lymphocytic Leukemia

    NCT02251548 · AbbVie Inc. · 1 U.S. investigator

    $3.1Mresearch payments

31. A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

    Completed · Phase 4 · COVID-19

    NCT07089706 · ModernaTX, Inc. · 5 U.S. investigators

    $3.1Mresearch payments

32. ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

    Active, not recruiting · Not applicable · Aortic Stenosis

    NCT03735667 · Boston Scientific Corporation · 72 U.S. investigators

    $3.1Mresearch payments

33. A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

    Recruiting · Phase 1, Phase 2 · Chronic Lymphocytic Leukemia

    NCT06697184 · Beone Medicines Ltd. · 6 U.S. investigators

    $3.0Mresearch payments

34. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

    Recruiting · Phase 1, Phase 2 · Ovarian Cancer

    NCT04590326 · Regeneron Pharmaceuticals, Inc. · 13 U.S. investigators

    $3.0Mresearch payments

35. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

    Completed · Phase 2 · Bipolar I Disorder

    NCT06605599 · AbbVie Inc. · 36 U.S. investigators

    $3.0Mresearch payments

36. A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

    Completed · Phase 2 · Alzheimer's Disease (AD)

    NCT05291234 · AbbVie Inc. · 31 U.S. investigators

    $3.0Mresearch payments

37. A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

    Active, not recruiting · Phase 3 · Relapsed/Refractory Follicular Lymphoma

    NCT04224493 · Epizyme, Inc. · 58 U.S. investigators

    $2.9Mresearch payments

38. Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

    Recruiting · Phase 1, Phase 2 · Recurrent Ovarian Cancer

    NCT03564340 · Regeneron Pharmaceuticals, Inc. · 11 U.S. investigators

    $2.9Mresearch payments

39. A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

    Active, not recruiting · Phase 3 · Episodic Migraine

    NCT06047457 · Ipsen Innovation · 62 U.S. investigators

    $2.9Mresearch payments

40. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

    Active, not recruiting · Phase 3 · Follicular Lymphoma (FL)

    NCT06191744 · AbbVie Inc. · 42 U.S. investigators

    $2.9Mresearch payments

41. Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

    Completed · Phase 2 · Tumor

    NCT05103358 · Aadi Bioscience, Inc. · 52 U.S. investigators

    $2.9Mresearch payments

42. Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

    Completed · Interstitial Lung Disease

    NCT05776225 · United Therapeutics Corporation · 44 U.S. investigators

    $2.9Mresearch payments

43. A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

    Active, not recruiting · Phase 1 · Metastatic Solid Tumor

    NCT06238479 · Eli Lilly and Company · 8 U.S. investigators

    $2.9Mresearch payments

44. A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

    Active, not recruiting · Phase 2 · Type 2 Diabetes

    NCT06037252 · Eli Lilly and Company · 25 U.S. investigators

    $2.8Mresearch payments

45. A Study of LY3867070 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT07021547 · Eli Lilly and Company · 1 U.S. investigator

    $2.8Mresearch payments

46. A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

    Recruiting · Phase 3 · Metastatic Head-and-neck Squamous-cell Carcinoma

    NCT06064877 · Aveo Pharmaceuticals, Inc. · 27 U.S. investigators

    $2.8Mresearch payments

47. CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    Completed · Phase 3 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    NCT04136171 · Ionis Pharmaceuticals, Inc. · 45 U.S. investigators

    $2.8Mresearch payments

48. A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

    Completed · Phase 3 · Dermatitis Atopic

    NCT06130566 · Sanofi US Services Inc. · 45 U.S. investigators

    $2.8Mresearch payments

49. Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

    Completed · Phase 3 · Influenza

    NCT06641180 · Sanofi Pasteur Inc. · 21 U.S. investigators

    $2.8Mresearch payments

50. Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

    Status unknown · Phase 2 · Melanoma, Malignant, of Soft Parts

    NCT02968303 · Eli Lilly and Company · 32 U.S. investigators

    $2.8Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.